Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. ACN
10. USO

Go back to Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences Corp. (NASDAQ: AVXL) Delayed: 2.58 +0.04 (1.57%)
Previous Close $2.54    52 Week High $8.30 
Open $2.50    52 Week Low $2.43 
Day High $2.67    P/E N/A 
Day Low $2.49    EPS $-0.22 
Volume 780,950       

Anavex Life Sciences Corp. (NASDAQ: AVXL) Delayed: 2.58 +0.04 (1.57%)
Previous Close $2.54    52 Week High $8.30 
Open $2.50    52 Week Low $2.43 
Day High $2.67    P/E N/A 
Day Low $2.49    EPS $-0.22 
Volume 780,950